RecruitingPrimary Biliary CholangitisPBC

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Eligible age

18+ yrs

Accepts

All genders

Locations

22 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.

Sponsor: Mirum Pharmaceuticals, Inc.

You may qualify if…

✓ Provide signed informed consent at the screening visit as well as comply with all study visits and requirements through the end of the study
✓ Male or female, age ≥18 years at the screening visit
✓ Confirmed diagnosis of PBC in line with the AASLD guidelines
✓ UDCA, anti-pruritic medication and PPAR agonist use will be allowed if meeting additional criteria
✓ Qualified pruritus associated with PBC as assessed by Adult ItchRO

You may not qualify if…

✕ Pruritus associated with an etiology other than PBC
✕ Evidence or clinical suspicion of decompensated cirrhosis or a history of decompensation events
✕ Current symptomatic cholelithiasis or inflammatory gallbladder disease
✕ History of small bowel surgery/resection impacting the terminal ileum that may disrupt the enterohepatic circulation.
✕ Evidence, history, or suspicion of other liver diseases; PBC patients with AIH are not excluded
✕ History of Liver transplantation